Share on StockTwits
 

Equities research analysts at Cormark assumed coverage on shares of Spectral Diagnostics (NASDAQ:DIAGF) in a research note issued to investors on Wednesday, AnalystRatings.NET reports. The firm set a “buy” rating on the stock.

Spectral Diagnostics (NASDAQ:DIAGF) remained flat at $0.5156 during trading on Wednesday. Spectral Diagnostics has a one year low of $0.179 and a one year high of $0.73. The stock has a 50-day moving average of $0.54 and a 200-day moving average of $0.46. The company’s market cap is $68.6 million.

DIAGF has been the subject of a number of other recent research reports. Analysts at Wedbush initiated coverage on shares of Spectral Diagnostics in a research note to investors on Tuesday, November 5th. They set an “outperform” rating and a C$5.00 price target on the stock.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.